Mediwound Ltd Cash Flow Conversion Efficiency
Mediwound Ltd cash flow conversion efficiency. Based on the latest financial reports, Mediwound Ltd (MDWD) has a cash flow conversion efficiency ratio of -0.044x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.60 Million) by net assets ($59.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mediwound Ltd (2012–2024)
Cash flow conversion efficiency of Mediwound Ltd from 2012 to 2024. This chart illustrates how Mediwound Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Mediwound Ltd stock price for real-time trading data and today's change.
Mediwound Ltd Cash Flow Conversion Ratio Explained
Mediwound Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mediwound Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mediwound Ltd ranked by their cash flow conversion efficiency. Also see Mediwound Ltd market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Long Table Growth Corp. Class A Ordinary Shares
NASDAQ:LTGR
|
-0.002x |
|
Kolon Corp
KO:002020
|
-0.014x |
|
Plano & Plano Desenvolvimento Imobiliário S.A
SA:PLPL3
|
-0.118x |
|
Forte Biosciences Inc
NASDAQ:FBRX
|
-0.166x |
|
Anhui Yuanchen Environmental Protection Science & Technology Co. Ltd.
SHG:688659
|
0.002x |
|
Texas Ventures Acquisition IV Corp Class A Ordinary Shares
NASDAQ:TVIV
|
-0.001x |
|
MK Electron Co. Ltd
KQ:033160
|
-0.039x |
|
Readly International AB
ST:READ
|
0.372x |
Annual Cash Flow Conversion Efficiency for Mediwound Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Mediwound Ltd from 2012 to 2024. Review MDWD free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $31.15 Million | $-13.62 Million | -0.437x | -32.03% |
| 2023-12-31 | $31.59 Million | $-10.46 Million | -0.331x | +69.58% |
| 2022-12-31 | $10.91 Million | $-11.88 Million | -1.089x | -155.96% |
| 2021-12-31 | $-4.58 Million | $-8.92 Million | 1.946x | +305.23% |
| 2020-12-31 | $7.27 Million | $-6.89 Million | -0.948x | -273.51% |
| 2019-12-31 | $15.17 Million | $8.29 Million | 0.546x | +140.34% |
| 2018-12-31 | $8.97 Million | $-12.15 Million | -1.355x | +20.80% |
| 2017-12-31 | $9.62 Million | $-16.45 Million | -1.710x | +19.18% |
| 2016-12-31 | $7.77 Million | $-16.45 Million | -2.116x | -153.42% |
| 2015-12-31 | $23.47 Million | $-19.60 Million | -0.835x | -117.08% |
| 2014-12-31 | $42.87 Million | $-16.49 Million | -0.385x | -178.22% |
| 2013-12-31 | $-19.80 Million | $-9.74 Million | 0.492x | +262.63% |
| 2012-12-31 | $15.63 Million | $-4.73 Million | -0.302x | -- |
About Mediwound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more